Patents by Inventor Mei Rosa NG

Mei Rosa NG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS OF GUANYLYL CYCLASE C (GCC) ANTIGEN BINDING AGENTS AND METHODS OF USE THEREOF
    Publication number: 20240050473
    Abstract: Antigen binding agents (e.g., single domain antibodies) that bind guanylyl cyclase C (GCC) and chimeric antigen receptors comprising GCC antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions comprising these antigen binding agents and fragments thereof are also disclosed. The invention also provides therapeutic methods for utilizing the antibodies and antigen-binding molecules are provided herein.
    Type: Application
    Filed: December 9, 2021
    Publication date: February 15, 2024
    Inventors: Gary SHAPIRO, Johara CHOUITAR, Xingyue HE, Mei Rosa NG
  • COMPOSITIONS OF GUANYLYL CYCLASE C (GCC) ANTIGEN BINDING AGENTS AND METHODS OF USE THEREOF
    Publication number: 20240033359
    Abstract: Antigen binding agents (e.g., single domain antibodies) that bind guanylyl cyclase C (GCC) are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions comprising these antigen binding agents and fragments thereof are also disclosed. The invention also provides therapeutic methods for utilizing the antibodies and antigen-binding molecules provided herein.
    Type: Application
    Filed: December 9, 2021
    Publication date: February 1, 2024
    Inventors: Gary SHAPIRO, Xingyue HE, Mei Rosa NG, Lorraine THOMPSON, Elena DE JUAN FRANCO, Steven VANCE
  • CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND USE THEREOF
    Publication number: 20230346938
    Abstract: The presently disclosed subject matter provides chimeric antigen receptors (CARs) that specifically target CD19 and cells comprising such CD19-targeted CARs. The presently disclosed subject matter further provides uses of the CD19-targeted CARs for treatment, e.g., for treating blood cancer.
    Type: Application
    Filed: October 24, 2022
    Publication date: November 2, 2023
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORAIL HOSPITAL FOR CANCER AND ALLIED DISEASES, MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Judith FEUCHT, Jorge MANSILLA-SOTO, Isabelle RIVIERE, Michel SADELAIN, Loic VINCENT, Gary SHAPIRO, Mei Rosa NG, Dan TAVARES, Xingyue HE